VANCOUVER, Canada, June 28 /PRNewswire/ --

- Peri-implantitis and Endodontic Applications

Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced that
the European Commission has approved its Periowave(TM) Photodisinfection
System for the treatment of dental peri-implant disease as well as for
endodontic disinfection. The European Commission decision applies to all 27
countries in the European Union as well as Iceland and Norway. These
additional indications build upon the previously approved Periowave(TM)
indication for the treatment of periodontal disease. In addition to the
European Union, Periowave(TM) is currently approved and marketed in Canada.

"We are pleased to be able to report on the review and approval by
European regulatory authorities of these expanded indications," stated
Carolyn Cross, President and CEO of Ondine. "European dental practitioners
are now equipped with a novel, alternative therapeutic option in the
treatment of the complex, polymicrobial infections that often characterise
intra-oral diseases such as peri-implantitis and periodontitis. Over time,
our goal is to provide the dental clinic with the leading, one-stop
disinfection technology to satisfy all therapeutic and prophylactic
disinfection requirements. Meanwhile in the US, we expect to submit our
application shortly for the gum disease indication to the FDA, building upon
our extensive experience with Periowave(TM) and the numerous satisfied
practitioners and patients."

About Peri-Implant Disease and Endodontics

Peri-implantitis affects 5% to 10% of implant patients and is a form of
gum disease caused by bacteria that colonise the tissues surrounding a dental
implant. If left untreated, peri-implantitis may lead to loss of the bone
structure supporting an implant, a major cause of implant failure.
Endodontics is a branch of dentistry concerned with the treatment of the pulp
chamber, or root canal, of the tooth. This chamber contains nerves, blood
vessels and cells regulating tooth development. Pulp decay is caused by a
bacterial invasion of the pulp chamber. If left untreated, this infection may
spread from the pulp chamber to tissues surrounding the root, causing further
breakdown and severe pain.

About Periowave(TM) and Photodisinfection

Periowave(TM) is a Photodisinfection system developed by Ondine that
utilises low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and
one or more lasers are used to activate the compounds and complete the
disinfection.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercialising leading-edge products utilising its
patented light-activated technology. Photodisinfection provides
broad-spectrum anti-microbial efficacy without encouraging the formation and
spread of antibiotic resistance.

The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Bothell, Washington, USA, and an international
office in St. Michael, Barbados. For additional information, please visit the
Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.